Holen Sie sich die Stockscreener-App
14.77
0.57%
-0.1062
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Why Did RARE Stock Slump 46% After-Hours? - Stocktwits
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - FinancialContent
Ultragenyx SVP Theodore Huizenga sells $2,252 in shares By Investing.com - Investing.com Canada
Ultragenyx SVP Theodore Huizenga sells $2,252 in shares - Investing.com
Ultragenyx (NASDAQ: RARE) exec sells 161 shares for RSU tax, keeps 69,146 - Stock Titan
$Ultragenyx Pharmaceutical (RARE.US)$ get ready - Moomoo
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder - Stocktwits
Why Ultragenyx Pharmaceutical (RARE) Is Down 40.3% After Angelman Trial Failure And Cost-Cut Plan - Yahoo Finance
Ultragenyx Pharmaceutical Inc. (RARE) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Ultragenyx (RARE) Stock Looks Fully Valued Following Its Phase 3 Setback - Yahoo Finance
Ionis Pharma prices first FDA-approved treatment for Alexander disease at $285,000 per dose - Reuters
RARE Stock Plunges As Ultragenyx Misses Key GTX-102 Trial - StocksToTrade
Ultragenyx Stock Crashes After GTX-102 Failure Despite Genglycos Win - timothysykes.com
Ultragenyx Stock Crashes As GTX-102 Failure Erases Optimism - StocksToTrade
RARE Stock Crashes As Ultragenyx Faces GTX-102 Trial Failure - timothysykes.com
The Goldman Sachs Group Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap UpTime to Buy? - MarketBeat
Rx Rundown: Eli Lilly, Ultragenyx, Novartis and more - Medical Marketing and Media
Barclays Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Ultragenyx Pharma Is Maintained at Overweight by Barclays - Moomoo
Ultragenyx Pharmaceutical (NASDAQ:RARE) Rating Lowered to "Hold" at Royal Bank Of Canada - MarketBeat
Wellington Management Group LLP Reduces Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout - Yahoo Finance
Ultragenyx: A 44% Crash After Trial Failure, Two Weeks After First Gene Therapy Approval - Kavout
Ultragenyx Pharmaceutical (RARE) Reports 61% Cornstarch Reduction In 96 Week Phase 3 Data - simplywall.st
Ultragenyx vows 'significant' cuts after experimental rare-disease drug flunks late-stage clinical trial - The Business Journals
Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $28.00 by Analysts at Jefferies Financial Group - MarketBeat
Ultragenyx: Angelman Study Setback Creates More Risk For Rare Disease Specialist - Seeking Alpha
Ultragenyx's Apazunersen Fails Phase III Trial | PharmExec - Pharmaceutical Executive
Ultragenyx Shares Crater After Angelman Syndrome Drug Fails Pivotal Trial - finance.biggo.com
Ultragenyx Trial Failure Revives Debate About How to Treat a Rare Neuro Disorder - MedCity News
Ultragenyx Pharmaceutical Target of Unusually Large Options Trading (NASDAQ:RARE) - MarketBeat
Ultragenyx Weighs Future of Angelman Syndrome ASO After Phase III Trial Failure - GenomeWeb
Citigroup Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipeline - Barron's
Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A TargetUltragenyx Pharmaceutical (NASDAQ:RARE) - Benzinga
Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $18.00 Price Target at TD Cowen - MarketBeat
Angelman wings clipped by Ultragenyx phase III bust - BioWorld News
Ultragenyx's Apazunersen Fails Phase 3 Angelman Syndrome Trial - BioPharm International
Ultragenyx mulls fate of rare disease programme on Phase III flop - Clinical Trials Arena
Ultragenyx stock downgraded after trial setback (RARE:NASDAQ) - Seeking Alpha
Why Is Ultragenyx (RARE) Up 6.4% Since Last Earnings Report? - Yahoo Finance
RARE Stock Down 46% as Phase III Angelman Syndrome Study Misses Goals - TradingView
Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study - BioPharma Dive
Ultragenyx sinks as Phase 3 Angelman trial miss slams a key pipeline bet - Quiver Quantitative
Ultragenyx Pharmaceutical (NASDAQ:RARE) Downgraded to "Neutral" Rating by Bank of America - MarketBeat
Ultragenyx Shares Drop Following Failed Phase III Clinical Trial - Pharmaceutical Executive
Ultragenyx Pharmaceutical (NASDAQ:RARE) Hits New 12-Month Low After Analyst Downgrade - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Lowered to $23.00 at Wedbush - marketbeat.com
Ultragenyx to slash costs after Angelman trial failure - pharmaphorum
We’re reading about an Ultragenyx failure, RevMed for lung cancer, and more - STAT
RARE Stock Craters As Ultragenyx Slashes Outlook After Trial Failure - timothysykes.com
RARE Stock Craters As Aspire Trial Failure Triggers Reset - StocksToTrade
William Blair Downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) to Market Perform - MarketBeat
Why Is Ultragenyx Stock Tumbling Today?Ultragenyx Pharmaceutical (NASDAQ:RARE) - Benzinga
RARE Stock Collapses After Angelman Drug Fails Late-Stage Trial - StocksToTrade
Canaccord cuts Ultragenyx stock price target on trial failure - Investing.com
Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Lowered to $33.00 at Cantor Fitzgerald - MarketBeat
HC Wainwright Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Lowered to Neutral Rating by JPMorgan Chase & Co. - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Rating Lowered to In-Line at Evercore - MarketBeat
Wells Fargo cuts Ultragenyx Pharma price target on trial failure By Investing.com - Investing.com Nigeria
Ultragenyx Angelman syndrome drug fails Phase III test - The Pharma Letter
Ultragenyx’s ‘high-risk’ Angelman bet fails, cratering stock and forcing strategic review - BioSpace
William Blair Downgrades Ultragenyx Pharmaceutical to Market Perform From Outperform - marketscreener.com
Evercore ISI Downgrades Ultragenyx Pharmaceutical to In Line From Outperform, Adjusts Price Target to $16 From $34 - marketscreener.com
Baird Downgrades Ultragenyx Pharmaceutical to Neutral From Outperform, Adjusts Price Target to $16 From $40 - marketscreener.com
Wells Fargo cuts Ultragenyx Pharma price target on trial failure - Investing.com
Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial - marketscreener.com
JPMorgan cuts Ultragenyx stock rating on trial setback - Investing.com
Baird cuts Ultragenyx stock rating on failed Angelman trial - Investing.com
Ultragenyx's Angelman syndrome drug fails pivotal Phase 3 trial - app.dealroom.co
Ultragenyx drops on Phase 3 trial failure for Angelman syndrome drug (RARE:NASDAQ) - Seeking Alpha
Ultragenyx stock plunges 40% on failed Angelman trial - Investing.com
Ultragenyx's ASO fails in Angelman syndrome, triggering sell-off - firstwordpharma.com
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):